1. How to use GuruFocus - Tutorials
  2. What Is in the GuruFocus Premium Membership?
  3. A DIY Guide on How to Invest Using Guru Strategies

Seattle Genetics Inc (SGEN) Files 10-K for the Fiscal Year Ended on December 31, 2017

February 15, 2018 | About:

Seattle Genetics Inc (NASDAQ:SGEN) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017. Seattle Genetics Inc is a development-stage biotech company. It develops monoclonal antibody-based therapies. Its lead product, Adcetris, has received approval for relapsed/refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma. Seattle Genetics Inc has a market cap of $7.81 billion; its shares were traded at around $54.06 with and P/S ratio of 17.01. Seattle Genetics Inc had annual average EBITDA growth of 1.20% over the past five years.

For the last quarter Seattle Genetics Inc reported a revenue of $129.6 million, compared with the revenue of $105.3 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $482.3 million, an increase of 15.3% from last year. For the last five years Seattle Genetics Inc had an average revenue growth rate of 17.4% a year.

The reported loss per diluted share was 88 cents for the year, compared with the loss per share of $0.51 in the previous year. The Seattle Genetics Inc had an operating margin of -40.6%, compared with the operating margin of -34.13% a year before. The 10-year historical median operating margin of Seattle Genetics Inc is -49.69%. The profitability rank of the company is 5 (out of 10).

At the current stock price of $54.06, Seattle Genetics Inc is traded at close to its historical median P/S valuation band of $59.15. The P/S ratio of the stock is 17.01, while the historical median P/S ratio is 18.60. The stock lost 14.03% during the past 12 months.

CEO Recent Trades:

  • President and CEO Clay B Siegall sold 18,832 shares of SGEN stock on 02/09/2018 at the average price of $49.75. The price of the stock has increased by 8.66% since.

Directors and Officers Recent Trades:

  • Director, 10% Owner Bros. Advisors Lp Baker bought 3,846,153 shares of SGEN stock on 02/01/2018 at the average price of $52. The price of the stock has increased by 3.96% since.

For the complete 20-year historical financial data of SGEN, click here.

Rating: 0.0/5 (0 votes)


Please leave your comment:

Performances of the stocks mentioned by insider

User Generated Screeners

blovedayBest Backtest Results
ralphdQuality Growth
salvatore34stock screener 2.0
DBrizanall 19SEP2018 942P
HOLKLSUEquity Income 2018 Q3 Energy a
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat